Active Ulcerative Colitis

Immunology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
1
5-ASAPhase 31 trial
Active Trials
NCT00603733Completed288Est. May 2011
Tillotts Pharma
Tillotts PharmaSwitzerland - Rheinfelden
1 program
1
Asacol®Phase 31 trial
Active Trials
NCT01257386CompletedEst. Mar 2013
Biogen
BiogenCAMBRIDGE, MA
1 program
1
BG9418Phase 21 trial
Active Trials
NCT00616434Completed123Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Tillotts PharmaAsacol®
Ferring Pharmaceuticals5-ASA
BiogenBG9418

Clinical Trials (3)

Total enrollment: 411 patients across 3 trials

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Start: Nov 2010Est. completion: Mar 2013
Phase 3Completed

Canadian Active & Maintenance Modified Pentasa Study

Start: Oct 2007Est. completion: May 2011288 patients
Phase 3Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Start: May 2008Est. completion: Mar 2010123 patients
Phase 2Completed

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space